Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?

Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe;Mocroft A;Reiss P;Kirk O;Mussini C;Girardi E;Morlat P;Stephan C;De Wit S;Doerholt K;Ghosn J;Bucher HC;Lundgren JD;Chene G;Miro JM;Furrer H. Collaborators: Weller I;Costagliola D;Ledergerber B;Lundgren J;Grarup J;Chene G;Touloumi G;Warszawski J;Meyer L;Dabis F;Krause MM;Ghosn J;Leport C;de Wolf F;Reiss P;Porter K;Dorrucci M;Sabin C;Gibb D;Fätkenheuer G;Del Amo J;Obel N;Thorne C;Mocroft A;Kirk O;Stephan C;Pérez Hoyos S;Antinori A;d'Arminio Monforte A;Tovo PA;de Martino M;Brockmeyer NH;Ramos J;Battegay M;Mussini C;Carnicer D;Tookey P;Casbona J;Miró JM;Castagna A;de Wit S;TORTI, Carlo;Teira R;Garrido M;Bucher H;Dabis F;Egger M;Furer H;Kirk O;Lewden C;Miro JM;Mocroft A;Newell ML;Phillips A;Sabin C;Stearne J;Telenti A;Collin Filleul F;Ellefson M;Fabre Colin C;Kjaer J;Schwimmer C;Paulsen M;Dedes N.

2010-01-01